The global interventional oncology market to grow at a CAGR of 11.17% during the period 2017-2021.
The report, Global Interventional Oncology Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
According to the report, the increasing cancer population is expected to drive the market growth. Cancer is one of the leading causes of death worldwide. Lung, liver, stomach, colorectal, breast, and esophageal cancers are prevalent among the population worldwide. According to the CDC in 2014, the number of adults diagnosed with cancer in the US stood at 20.3 million. The number of patient visits to physicians' offices for cancer stood at 20.1 million in 2014.
Also, according to some research findings,the number of individuals diagnosed with cancer reached approximately 14.5 to 15 million in 2014 and is expected to reach 19 million by 2024. The majority of cancers at chronic stages cannot be treated with conventional drugs. This is expected to increase the demand for interventional oncology procedures, such as tissue ablation and embolization, thereby driving the market growth.
- Boston Scientific
- Merit Medical
Other prominent vendors
- Baylis Medical
- C. R. Bard
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Market segmentation by procedure
PART 07: Geographical segmentation
PART 08: Market drivers
PART 09: Impact of drivers
PART 10: Market challenges
PART 11: Impact of drivers and challenges
PART 12: Market trends
PART 13: Vendor landscape
PART 14: Key vendor analysis
PART 15: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/6zn4vr/global